Published in:
01-04-2011 | Erratum
Erratum to: Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study
Published in: Arthritis Research & Therapy | Issue 1/2011
Login to get accessExcerpt
After publication of our recent article [1], we noticed an error in the unit for the area under the time-concentration curve between 0 and 12 hours (AUC0-12 h). Throughout the article and Table 1 the unit should be mg·h/L (mg multiplied by hour per L) not mg/hour/L.
Table 1
Inclusion characteristics (of the 26 systemic lupus erythematosus patients) and their ability to predict clinical outcome (univariate analysis)
|
Total
|
Successes
|
Failures
|
||
|---|---|---|---|---|
|
Inclusion characteristic
|
n= 26
|
n= 17
|
n= 8
|
Pvaluea
|
|
Demographic
|
||||
|
Females/Males, number
|
16/10
|
12/5
|
4/4
|
0.28b
|
|
Age, years
|
46 (35-61)a
|
46.5 (35-61)
|
46 (38-61)
|
0.9
|
|
Body weight, kg
|
60 (56-75)
|
60 (56-75)
|
62 (58-82.5)
|
0.62
|
|
Disease
|
||||
|
Duration before entry, months
|
11 (7-14)
|
11 (7-12)
|
10 (6-13)
|
0.30
|
|
SLEDAI score
|
0 (0-2)
|
0 (0-2)
|
0 (0-2)
|
0.20
|
|
C3, g/L
|
1 (0.6-1.1)
|
1 (0.9-1.1)
|
0.8 (0.56-0.96)
|
0.21
|
|
C4, g/L
|
0.2 (0.1-0.2)
|
0.2 (0.1-0.2)
|
0.2 (0.16-0.24)
|
0.78
|
|
Anti-double-stranded DNA, IU/mL
|
24 (6-51)
|
8 (1-32)
|
38 (9-55)
|
0.19
|
|
Biological
|
||||
|
GFR, mL/minute
|
95 (67-125)
|
95 (67-125)
|
93.5 (76-109)
|
0.64
|
|
Albumin, g/L
|
40 (39.8-43.8)
|
40 (37.9-43.8)
|
42.8 (40-46.9)
|
0.33
|
|
Aspartate aminotransferase, IU/L
|
23 (19-26)
|
23 (17.5-24.5)
|
28 (20-33)
|
0.26
|
|
Alanine aminotransferase, IU/L
|
22 (15-29)
|
19 (13-24.5)
|
25 (19-37)
|
0.21
|
|
γ-Glutamyltransferase, IU/L
|
24 (17-63)
|
23 (17-21)
|
42 (17-61)
|
0.92
|
|
Treatment
|
||||
|
MMF, g/day
|
2 (2-2)
|
2 (2-2)
|
2 (2-2)
|
0.9
|
|
Corticosteroids, mg/day
|
11 (7-35)
|
10 (5-20)
|
15 (7-45)
|
0.37
|
|
Months of MMF therapy
|
2 (1-3)
|
2 (1-3)
|
2 (1-3)
|
0.56
|
|
Months of corticosteroids
|
10 (6-13)
|
10 (5-15)
|
9 (5-14)
|
0.12
|
|
MPA pharmacokinetic parameters
|
||||
|
AUC0-12 h' mg·hour/L
|
64.7 (38.2-82)
|
73.1 (61.8-95)
|
37.7 (32-43.7)
|
0.003
|
|
Cmax' mg/L
|
16.1 (9.5-18.5)
|
16.3 (9.7-17.4)
|
13.3 (7-22.5)
|
0.69
|
|
Tmax' hours
|
1 (1-2)
|
1 (1-2)
|
1.1 (1-2)
|
0.82
|
|
C12 h' mg/L
|
2.4 (1.5-4.1)
|
3.7 (2.3-4.9)
|
1.5 (0.6-2.1)
|
0.008
|
|
MPAG pharmacokinetic parameters
|
||||
|
AUC0-12 h' mg·hour/L
|
775.3 (475-1,026)
|
791 (635-1,166)
|
678.8 (426-840.6)
|
0.22
|
|
Tmax' hours
|
2 (2-3)
|
2.3 (2-3)
|
1.3 (1-2)
|
0.01
|
|
C12 h' mg/L
|
32.1 (24.3-41.9)
|
34.7 (26.4-49.2)
|
29.8 (15.5-40)
|
0.26
|
|
MPAG/MPA AUC0-12 h ratio
|
11.5 (8.3-20.7)
|
10.9 (6.2-14.8)
|
18.7 (14.1-22.7)
|
0.07
|
|
MPAG/MPA C12 h ratio
|
11.5 (6.8-17.3)
|
10.2 (6.3-15)
|
18.7 (11.5-47.2)
|
0.02
|